Company: SCLXW
Filing Date: 2025-08-14
Form Type: 424B3
Source: 0000950170-25-108229
Chunk: 10

Company: Scilex Holding Co
Filing Date: 2025-08-14
Form: 424B3
Chunk 10
---
 BDO and April 2024 RDO included in accrued expenses and accounts payables  | $                         |       — |   |     | $    |   1,440 |   |
| Deferred transaction costs related to Semnur Business Combination included in accrued expenses and account payable | $                         |   2,209 |   |     | $    |       — |   |
| Additions to intangible assets included in accrued expenses                                                        | $                         |   1,000 |   |     | $    |       — |   |
| Acquisition of interest in joint venture in accrued expenses                                                       | $                         |   1,100 |   |     | $    |       — |   |

See accompanying notes to unaudited condensed consolidated financial statements.

<div align='center'>5

SCILEX HOLDING COMPANY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)</div>

1. Nature of Operations and Basis of Presentation

Organization and Principal Activities

Scilex Holding Company (“Scilex” and together with its controlled subsidiaries, the “Company”) is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company was originally formed in 2019 and currently has six subsidiaries, of which the following four subsidiaries are wholly owned: Scilex Inc. (“Legacy Scilex”), Scilex Pharmaceuticals Inc. (“Scilex Pharma”), SCLX DRE Holdings LLC, and SCLX Stock Acquisition JV LLC (“SCLX JV”); and the following two subsidiaries are controlled by Scilex: Scilex Bio, Inc. (“Scilex Bio”) and Semnur Pharmaceuticals, Inc. (“Semnur”). The business combination with Vickers (the “Business Combination”) was closed in November 2022.

The Company launched its first commercial product in October 2018, ZTlido (lidocaine topical system) 1.8% (“ZTlido”), a prescription lidocaine topical system that is designed with novel technology to address the limitations of current prescription lidocaine therapies by providing significantly improved adhesion and continuous pain relief throughout the 12-hour administration period. In June 2022, the Company in-licensed the exclusive right to commercialize GLOPERBA (colchicine USP) oral solution (“GLOPERBA”), a U.S. Food and Drug Administration